Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: A NICE single technology appraisal

PharmacoEconomics

Volumn 31, Issue 6, 2013, Pages 471-478

  Rafia, Rachid ^a   Simpson, Emma ^a   Stevenson, Matt ^a   Papaioannou, Diana ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; TRABECTEDIN;

ADVANCED CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIOXOLES; DISEASE-FREE SURVIVAL; GREAT BRITAIN; HUMANS; MODELS, THEORETICAL; NEOPLASM METASTASIS; QUALITY-ADJUSTED LIFE YEARS; SARCOMA; SURVIVAL RATE; TETRAHYDROISOQUINOLINES;

EID: 84877941984     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0044-7     Document Type: Review

References (37)

1. National Institute for Health and Clinical Excellence. Guide to the single technology (STA) process. London: NICE; 2006.
2. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347-9.
3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351-62.
4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439-48.
5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133-40.
6. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951-61.
7. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(12):1051-62.
8. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(1):35-46.
9. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(2):137-46.
10. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257-70.
11. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(6):483-95.
12. Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for severe persistent asthma in children aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991-1004.
13. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(12):1119-32.
14. Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(1):15-24.
15. Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(2):101-10.
16. Spackman E, Rice S, Norman G, Suh D-C, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2 positive metastatic gastric cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(3):185-94.
17. Simpson EL, Fitzgerald P, Evans P, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(4):269-75.
18. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013-0043-8.
19. Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013-0049-2.
20. Tosh J, Archer R, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013-0052-7.
21. Kearns B, Lloyd-Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013- 0050-9.
22. Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. In press.
23. National Institute for Health and Clinical Excellence. Soft tissue sarcoma: trabectedin. London: NICE; 2010. http://guidance.nice.org.uk/TA/Wave18/ 26. Accessed 14 Mar 2013.
24. National Institute for Health and Clinical Excellence. Improving outcomes for people with sarcoma. London: NICE; 2006.
25. Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc'h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. Plos One. 2011;6(8):e20294.
26. National Institute for Health and Clinical Excellence. Final scope: STA, trabectedin for the treatment of advanced metastatic soft tissue sarcoma. London: NICE; 2008.
27. European Medicines Agency. EMEA/COMP position on review of criteria for orphan designation of an orphan medicinal product submitted for marketing authorisation: ecteinascidin 743 (Yondelis; INN: trabectedin). London: EMA; 2007.
28. PharmaMar. Manufacturer submission: report submitted to NICE. London: NICE; 2009.
29. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188-96.
30. Le Cesne A, Blay JY, Judson I, Van OA, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. [erratum appears in J Clin Oncol. 2005 Aug 1;23(22):5276]. J Clin Oncol. 2005;23(3):576-84.
31. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890-9.
32. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480-90.
33. Judson I, Al-Muderis O, Scott D, Lloyd A, Alonso F, Garcia B. Cost of management of metastatic soft tissue sarcoma [poster no. LB70]. NCRI Cancer Conference; Birmingham; 4-7 Oct 2007.
34. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;21(6):84.
35. National Institute for Health and Clinical Excellence. Appraising treatments which may extend life, at the end of life. London: NICE; 2010.
36. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
37. Simpson EL, Rafia R, Stevenson MD, Papaioannou D. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Health Technol Assess. 2010;14(Suppl. 1):63-7. doi: 10.3310/hta14Suppl1/09.